Adastra Holdings Enters into Agreements to Sell Subsidiaries

Adastra Holdings Enters into Agreements to Sell Subsidiaries

Adastra Holdings Ltd. (CSE: XTRX,OTC:XTXXF) (FSE: D2E0) (the "Company") announces that it has entered into agreements to sell all of the issued and outstanding shares of its wholly-owned subsidiaries, Adastra Labs Holdings (2019) Ltd. ("Adastra Labs"), 1178562 B.C. Ltd. ("1178562"), and Adastra Brands Inc. ("Adastra Brands").

The aggregate consideration for all transactions is $4,000,000, including $495,000 for the sale of Adastra Labs payable by way of a 12% interest-bearing promissory note, $3,500,000 for the sale of 1178562 satisfied by the purchaser's assumption of the existing mortgage debt on the Langley, BC based property owned by 1178562 (the "Property"), and $5,000 cash for the sale of Adastra Brands.

In connection with the share purchase agreements, 1178562 and the Company's wholly owned subsidiary, Adastra Labs Inc., agreed to enter into a lease agreement pursuant to which 1178562 will lease 13,000 square feet of warehouse and office space located at the Property to Adastra Labs Inc. in consideration for $35,000 per month. Additionally, Adastra Brands and the Company agreed to enter to into an intellectual property licensing agreement pursuant to which Adastra Brands will license certain trademarks to the Company for nominal consideration.

The sale of the Company's subsidiaries aligns with the Company's strategy to strengthen its balance sheet, reduce debt, and streamline operations. Through the related leaseback and intellectual property licensing agreements entered into in connection with the transactions, the Company is in a position to continue to operate from its existing facility and retain the right to use its established brands and trademarks.

The transactions are expected to be completed shortly and remain subject to customary closing conditions.

About Adastra Holdings Ltd.

Adastra has become one of Canada's leaders in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. It serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 2,000 locations across Canada, Adastra's Phyto Extractions and Endgame Extracts brands are now well established with a growing distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Adastra partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market, with the ultimate aim of addressing the needs of patients. For more information, visit: www.adastraholdings.ca.

For additional information, please contact:
Jonathan Edwards, CFO
(778) 715-5011
info@adastraholdings.ca

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "expected," "anticipated," "will," or similar expressions. Forward-looking statements in this press release include but are not limited to the Company or its subsidiaries entering into a lease agreement and intellectual property licensing agreement, the Company strengthening its balance sheet, reducing debt, and streamlining operations, the Company continuing to operate from its existing facility and retaining the right to use its established brands and trademarks, the transactions completing shortly. These forward-looking statements are made as of the date of this press release. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. Although the Company believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. Such factors include, among others, the ability to satisfy customary closing conditions and obtain any necessary regulatory approvals. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269777

News Provided by Newsfile via QuoteMedia

XTRX:CNX
The Conversation (0)
adastra labs

Adastra Holdings

Purveyor of Quality Cannabis Derivatives and Award-Winning Extracts

Adastra Receives Controlled Substances Dealer's License

Adastra Receives Controlled Substances Dealer's License

Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to announce that the Company has received its Controlled Drug and Substances Dealer's... Keep Reading...
Adastra Holdings Reports Record Second Quarter Results; Momentum Accelerating in Second Half of the Year

Adastra Holdings Reports Record Second Quarter Results; Momentum Accelerating in Second Half of the Year

Record gross revenues of $5.34M YTD 2022, representing 192% growth compared to YTD 2021.Q2 2022 gross revenues of $3.05M, representing an increase of 33% over last quarter (Q1 2022).Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on... Keep Reading...
Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada

Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada

Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales License from Health Canada which now... Keep Reading...
Adastra Holdings Continues to Execute on Transformational Strategy; New Product Launches; Outlines Growth Strategy

Adastra Holdings Continues to Execute on Transformational Strategy; New Product Launches; Outlines Growth Strategy

Endgame Extracts brand launched in BC in Q1 2022 with a 100% case sell-through achieved in 48-hours; Endgame is currently ranked #3 and #4 for its shatter sales in BC – with launches planned for other large Canadian markets ( Alberta and Ontario ) to follow Adastra continues to add new revenue... Keep Reading...
Adastra Holdings Reports First Quarter Results

Adastra Holdings Reports First Quarter Results

Generated record gross revenues of $2,286,721 in Q1 2022, representing 288% growth compared to Q1 2021 Maintained a strong capital position in Q1 2022 with $28,176,801 in assets, and $6,712,176 in liabilities Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("Adastra" or the "Company") is pleased... Keep Reading...
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
Field of cannabis plants under bright sunlight.

Cannabis Market Update: H1 2025 in Review

The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...

Latest Press Releases

Related News